The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

(NASDAQ:SRPT) plunged to $19.91, down $16.27, or almost 45%, on word of a second death by acute liver failure (ALF) with Elevidys (delandistrogene moxeparvovec), the approved gene therapy for patients ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...